Method of treating cancer of the prostate

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6384044
SERIAL NO

09715101

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Cancer of the prostate in human male patients even at an advanced state with metastasis to other organs, is treated by the administration, preferably at bedtime, to the patient by a pharmacologically effective mode of an essentially pure opiate receptor antagonist, typified by Naltrexone and Naloxone, exerting substantially higher blocking action for Mu opiate receptor sites than against Delta opiate receptor sites at a low dose concentration which produces therapeutic results corresponding to those obtained by the administration of Naltrexone at a low dosage level in the range of 1.0 mg. to 10 mg. per day and at which Delta receptor blocking activity is at most small and Mu receptor blocking activity is substantial. Naltrexone is suitable for oral administration and is preferred.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
YOUNG JACQUELINE MS139 E 33RD STREET APT 10K NEW YORK NY 10016

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bihari, Bernard 29 W. 15th St., New York, NY 10011 7 246

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation